Dr. Neil Fleshner and his research team from the University Health Network in Toronto are presently conducting a trial to determine if the Red Bull energy drink reduces fatigue in prostate cancer patients receiving LHRH agonist therapy. The primary outcome of this phase II trial, namely fatigue reduction, is being measured by the Bruera global fatigue severity scale, while improvement in quality of life is determined according to the Medical Outcomes Study Short-Form (SF-36). Patients with a histologically confirmed prostate cancer diagnosis undergoing LHRH-agonist therapy for at least the past 6 months, and a life expectancy of at least 1 year, are invited to apply. As Red Bull is a caffeinated beverage, patients having experienced a myocardial infarction within the past 6 months, liver or kidney problems, or hypersensitivity to caffeine are not elligible to participate.
To read more about this trial, click here.
No comments:
Post a Comment